BIOA

Business Context and Reporting Period

BioAge Labs, Inc. (Nasdaq: BIOA) is a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, primarily obesity. The company's lead candidate, azelaprag, is an orally available small molecule currently in Phase 2 clinical trials. This Form 10-Q covers the quarterly period ended September 30, 2024. During this period, the company completed its Initial Public Offering (IPO) on September 25, 2024, and converted all outstanding redeemable convertible preferred stock into common stock.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no product revenue to date.

Material Changes vs. Prior Period

• Liquidity Transformation: Cash and cash equivalents increased from $21.6 million at year-end 2023 to $334.5 million at September 30, 2024. This surge was driven by the IPO and a concurrent private placement, which generated approximately $211.8 million in net proceeds from the public offering and $9.9 million from the private placement.
• Capital Structure: All outstanding redeemable convertible preferred stock (approx. $342.8 million carrying value) and convertible promissory notes were converted into common stock in connection with the IPO. Consequently, the company moved from a stockholders' deficit of $(173.4) million to equity of $313.7 million.
• Expense Growth: Operating expenses increased significantly, with R&D expenses rising 206% quarter-over-quarter (Q3 2024 vs. Q3 2023) to $20.0 million. This increase is primarily attributed to the ongoing Phase 2 STRIDES trial for azelaprag and manufacturing costs.
• Debt Reduction: The company extinguished $20.7 million in convertible promissory notes and related derivative liabilities upon conversion to preferred stock in February 2024. The remaining debt consists of a term loan with a principal balance of $9.5 million.

Guidance, Outlook, and Risks

• Cash Runway: Management estimates that existing cash, combined with proceeds from the underwriters' option exercise (completed October 1, 2024, adding ~$27.6 million), is sufficient to fund operations into 2029.
• Clinical Pipeline:
  • STRIDES Trial: Assessing azelaprag in combination with tirzepatide (Zepbound); topline results expected in Q3 2025.
  • STRIDES 2 Trial: Assessing azelaprag in combination with semaglutide (Wegovy); initiation expected H1 2025, results H2 2026.
  • STRIDES T2D: Azelaprag monotherapy for Type 2 Diabetes; initiation expected H1 2025.
  • NLRP3 Inhibitors: IND submission expected H2 2025 for neuroinflammation indications.
• Material Weaknesses: The company disclosed material weaknesses in internal controls over financial reporting related to insufficient internal resources, lack of effective IT general controls, and inadequate risk assessment. Remediation efforts are underway, including hiring additional finance personnel and engaging consultants.
• Risks: Key risks include the uncertainty of clinical trial outcomes, dependence on third-party manufacturers (including potential supply chain disruptions related to Chinese biotechnology companies under the proposed BIOSECURE Act), and the need for additional capital if development timelines extend beyond current projections.

Investor Verification Checklist

• Capital Efficiency: Verify the burn rate relative to the $334.5 million cash balance to confirm the 2029 runway estimate, considering the high cost of Phase 2 trials.
• Internal Controls: Monitor the progress of remediation for the disclosed material weaknesses in internal controls, as failure to remediate could impact future reporting reliability.
• Manufacturing Supply Chain: Assess the impact of the proposed BIOSECURE Act on the company's reliance on Chinese CDMOs (specifically WuXi Apptec) for manufacturing azelaprag.
• Clinical Milestones: Track the enrollment and topline data release dates for the STRIDES and STRIDES 2 trials, as these are critical value drivers.
• Debt Covenants: Review the terms of the remaining $9.5 million term loan to ensure compliance with covenants and understand the impact of the 16.4% effective interest rate on future cash flows.